Kapake

Paracetamol, the active ingredient in Kapake, is an analgesic presented as an oral tablet for oral use. It is combined with codeine phosphate to provide relief of mild to moderate pain and to reduce fever in adult patients. The formulation leverages the synergistic action of a central COX inhibitor and a μ‑opioid receptor agonist, offering effective symptom control in various acute and chronic conditions.

GNH USA supplies Kapake as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare institutions worldwide.

Kapake, containing paracetamol and codeine phosphate, is used to manage pain and fever through central analgesic pathways.

- Mild to moderate pain: provides effective analgesia for conditions such as headache, dental pain, musculoskeletal discomfort. - Post‑operative pain: helps control pain after surgical procedures, facilitating recovery and mobilization. - Fever: reduces elevated body temperature associated with infections or inflammatory states. - Dysmenorrhea: alleviates menstrual cramps by diminishing uterine muscle contractions and pain perception.

Kapake may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Dizziness - Constipation - Drowsiness

Serious or Rare Side Effects: - Respiratory depression - Severe allergic reaction (anaphylaxis) - Hepatotoxicity with overdose - Dependence or addiction potential

When prescribing Kapake, clinicians should consider several safety measures to minimise risk.

- Assess liver function: evaluate hepatic status before initiating therapy. - Monitor respiratory status: watch for signs of depression, especially in opioid‑naïve patients. - Avoid concurrent CNS depressants: limit use with benzodiazepines, antihistamines or alcohol. - Use caution in renal impairment: adjust dosing if necessary. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Kapake can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Alcohol: increases risk of hepatotoxicity and central nervous system depression. - MAO inhibitors: may potentiate opioid effects leading to severe sedation. - Other opioid analgesics: additive respiratory depression risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance bleeding tendency. - Antihistamines: can increase drowsiness and dizziness. - CYP2D6 inhibitors (e.g., fluoxetine): may raise codeine plasma levels, increasing opioid effects.